SSA
AKRO

Schonfeld Strategic Advisors’s Akero Therapeutics AKRO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-110,000
Closed -$5.56M – 1842
2023
Q3 		$5.56M Buy
+110,000
New +$5.12M 0.04% 512

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's AKRO Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 303,814 shares — an estimated $14.4M sold.

Schonfeld Strategic Advisors first reported a position in AKRO in Q2 2022 and held it in 14 quarters. The position peaked at $17.6M in Q1 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 303,814 Akero Therapeutics shares in Q4 2025, an estimated $14.4M.
  • Schonfeld Strategic Advisors first reported a position in Akero Therapeutics in Q2 2022 and held it in 14 quarters.
  • Schonfeld Strategic Advisors's Akero Therapeutics position peaked at $17.6M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.